clonidine has been researched along with Nervous System Disorders in 10 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
Excerpt | Relevance | Reference |
---|---|---|
" Narcotics are used for the euphoria they provide; however, chronic use results in physiological and psychological changes." | 2.37 | Narcotic withdrawal in the emergency department. ( Freitas, PM, 1985) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 5 (50.00) | 18.7374 |
1990's | 2 (20.00) | 18.2507 |
2000's | 1 (10.00) | 29.6817 |
2010's | 2 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kubo, Y | 1 |
Dworkin, RH | 1 |
Treggiari, MM | 1 |
Romand, JA | 1 |
Martin, JB | 1 |
Reverdin, A | 1 |
Rüfenacht, DA | 1 |
de Tribolet, N | 1 |
Coombs, DW | 1 |
Goldberg-Stern, H | 1 |
Atlas, D | 1 |
Schwartz, L | 1 |
Achiron, A | 1 |
Ziv, I | 1 |
Djaldetti, R | 1 |
Zoldan, Y | 1 |
Melamed, E | 1 |
Metz, SA | 1 |
Halter, JB | 1 |
Porte, D | 1 |
Robertson, RP | 1 |
Moreau, R | 1 |
Caine, ED | 1 |
McBride, MC | 1 |
Chiverton, P | 1 |
Bamford, KA | 1 |
Rediess, S | 1 |
Shiao, J | 1 |
Sandyk, R | 1 |
Gillman, MA | 1 |
Iacono, RP | 1 |
Bamford, CR | 1 |
Freitas, PM | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Cervical Sympathetic Block to Increase Cerebral Blood Flow in Patients With Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage[NCT05230134] | 10 participants (Anticipated) | Interventional | 2023-07-27 | Enrolling by invitation | |||
Stellate Ganglion Block for the Treatment of COVID-19-Induced Olfactory Dysfunction: A Prospective Pilot Study[NCT05445921] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2022-09-01 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Participants will be asked to complete the ODOR, which is a patient-reported outcome measure assessing physical problems, functional limitations, and emotional consequences of olfactory dysfunction.~The ODOR has a minimum score of 0 and a maximum score of 112 with higher scores indicating a greater degree of impairment and limitation. The minimal clinically important difference is a change of 15 points." (NCT05445921)
Timeframe: baseline, 5-10 days post SGB #1, and 1 month
Intervention | score on a scale (Median) | ||
---|---|---|---|
ODOR at Baseline | ODOR at 1 Week | ODOR at 1 Month | |
Stellate Ganglion Block | 62 | 57 | 50.5 |
"Participants will complete the 40-item scratch and sniff UPSIT and mean change will be assessed.~The UPSIT has a minimum score of 0 and maximum score of 40 with lower scores indicating a greater degree of impairment. An UPSIT score of >33 for men and >34 for women is considered normosmic, and the minimal clinically important difference is a change of 4 points." (NCT05445921)
Timeframe: baseline, 5-10 days, and 1 month
Intervention | units on a scale (Median) | ||
---|---|---|---|
UPSIT at Baseline | UPSIT at 1 Week | UPSIT at 1 Month | |
Stellate Ganglion Block | 16.5 | 21 | 22.5 |
Participants will be asked about their change in olfactory dysfunction on a 7-point Likert scale from much better to much worse. (NCT05445921)
Timeframe: 5-10 days post SGB #1 and 1 month
Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CGI-I for Smell Loss at 1 Week71922197 | CGI-I for Smell Loss at 1 Month71922197 | CGI-I for Smell Distortion at 1 Week71922197 | CGI-I for Smell Distortion at 1 Month71922197 | CGI-I for Taste Loss at 1 Week71922197 | CGI-I for Taste Loss at 1 Month71922197 | CGI-I for Taste Distortion at 1 Week71922197 | CGI-I for Taste Distortion at 1 Month71922197 | |||||||||||||||||||||||||
About the Same | Slightly Better | Much Better | Moderately Better | |||||||||||||||||||||||||||||
Stellate Ganglion Block | 8 | |||||||||||||||||||||||||||||||
Stellate Ganglion Block | 10 | |||||||||||||||||||||||||||||||
Stellate Ganglion Block | 9 | |||||||||||||||||||||||||||||||
Stellate Ganglion Block | 11 | |||||||||||||||||||||||||||||||
Stellate Ganglion Block | 6 | |||||||||||||||||||||||||||||||
Stellate Ganglion Block | 1 | |||||||||||||||||||||||||||||||
Stellate Ganglion Block | 15 | |||||||||||||||||||||||||||||||
Stellate Ganglion Block | 4 | |||||||||||||||||||||||||||||||
Stellate Ganglion Block | 0 | |||||||||||||||||||||||||||||||
Stellate Ganglion Block | 14 | |||||||||||||||||||||||||||||||
Stellate Ganglion Block | 3 | |||||||||||||||||||||||||||||||
Stellate Ganglion Block | 2 | |||||||||||||||||||||||||||||||
Stellate Ganglion Block | 13 | |||||||||||||||||||||||||||||||
Stellate Ganglion Block | 12 | |||||||||||||||||||||||||||||||
Stellate Ganglion Block | 5 |
Participants will be asked about the severity of their olfactory dysfunction (and gustatory dysfunction) on a 5-point Likert scale from no smell loss to severe smell loss. (NCT05445921)
Timeframe: baseline, 5-10 days, and 1 month
Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CGI-S for Smell Loss at Baseline71922197 | CGI-S for Smell Loss at 1 Week71922197 | CGI-S for Smell Loss at 1 Month71922197 | CGI-S for Smell Distortion at Baseline71922197 | CGI-S for Smell Distortion at 1 Week71922197 | CGI-S for Smell Distortion at 1 Month71922197 | CGI-S for Taste Loss at Baseline71922197 | CGI-S for Taste Loss at 1 Week71922197 | CGI-S for Taste Loss at 1 Month71922197 | CGI-S for Taste Distortion at Baseline71922197 | CGI-S for Taste Distortion at 1 Week71922197 | CGI-S for Taste Distortion at 1 Month71922197 | |||||||||||||||||||||||||||||||||||||||||||||||||
No Problem | Very Mild Problem | Mild Problem | Moderate Problem | Severe Problem | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stellate Ganglion Block | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stellate Ganglion Block | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stellate Ganglion Block | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stellate Ganglion Block | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stellate Ganglion Block | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stellate Ganglion Block | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stellate Ganglion Block | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stellate Ganglion Block | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stellate Ganglion Block | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stellate Ganglion Block | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stellate Ganglion Block | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stellate Ganglion Block | 11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stellate Ganglion Block | 6 |
4 reviews available for clonidine and Nervous System Disorders
Article | Year |
---|---|
[Carrier-mediated Transport of Cationic Drugs across the Blood-Tissue Barrier].
Topics: Angiogenesis Inhibitors; Biological Transport; Blood-Brain Barrier; Blood-Retinal Barrier; Cation Tr | 2015 |
[Short and long-term effects of clonidine on sympathetic activity, hemodynamics and renal metabolism of water and sodium in patients with liver cirrhosis].
Topics: Clonidine; Diuresis; Glomerular Filtration Rate; Hemodynamics; Humans; Liver Cirrhosis; Natriuresis; | 1992 |
Clonidine in neuropsychiatric disorders: a review.
Topics: Clonidine; Humans; Nervous System Diseases | 1987 |
Narcotic withdrawal in the emergency department.
Topics: Clonidine; Emergency Service, Hospital; Endorphins; Humans; Methadone; Narcotics; Nervous System Dis | 1985 |
1 trial available for clonidine and Nervous System Disorders
Article | Year |
---|---|
Cervical sympathetic block to reverse delayed ischemic neurological deficits after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Anesthetics, Local; Angiography, Digital Subtraction; Autonomic Nerve Block; Brain Ischemia; | 2003 |
Cervical sympathetic block to reverse delayed ischemic neurological deficits after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Anesthetics, Local; Angiography, Digital Subtraction; Autonomic Nerve Block; Brain Ischemia; | 2003 |
Cervical sympathetic block to reverse delayed ischemic neurological deficits after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Anesthetics, Local; Angiography, Digital Subtraction; Autonomic Nerve Block; Brain Ischemia; | 2003 |
Cervical sympathetic block to reverse delayed ischemic neurological deficits after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Anesthetics, Local; Angiography, Digital Subtraction; Autonomic Nerve Block; Brain Ischemia; | 2003 |
5 other studies available for clonidine and Nervous System Disorders
Article | Year |
---|---|
Mechanism-based treatment of pain.
Topics: Analgesics; Animals; Clonidine; Diabetic Neuropathies; Female; Humans; Male; Nervous System Diseases | 2012 |
Neurotoxicity of new intraspinal agents.
Topics: Analgesia; Clonidine; Humans; Injections, Spinal; Nervous System Diseases; Pain | 1984 |
Detection and measurement of an endogenous clonidine-displacing substance in human cerebrospinal fluid.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Binding, Competitive; Cerebrospinal Fluid Proteins; Cere | 1993 |
Autonomic epilepsy: clonidine blockade of paroxysmal catecholamine release and flushing.
Topics: Autonomic Nervous System; Carbamazepine; Catecholamines; Climacteric; Clonidine; Epilepsy; Epilepsy, | 1978 |
Tourette's syndrome in Monroe County school children.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior; Child; Child, Preschool; Clonid | 1988 |